{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-023064","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.361840+00:00","generated_at":"2026-06-02T00:53:20.532887+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ovid Therapeutics reports Q1 2024 net loss of $11.7M; cash $90.3M; Takeda Phase 3 soticlestat data expected by Sep 2024","bullets":["Net loss $11.7M ($0.17/share) vs $13.4M ($0.19) in Q1 2023; revenue $148K.","Cash $90.3M as of Mar 31, 2024; expected to fund operations into H1 2026.","Takeda completed Phase 3 trials for soticlestat in LGS and Dravet; topline data expected in H1 2024 fiscal year (by Sep 2024).","OV888 (GV101) Phase 1 MAD complete; no serious AEs; Phase 2 in CCM expected H2 2024.","Ovid retains 87% interest in soticlestat milestones (up to $660M) and tiered royalties up to 20%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-023064","json":"https://secwatch.observer/filing/0001628280-24-023064.json","markdown":"https://secwatch.observer/filing/0001628280-24-023064.md","text":"https://secwatch.observer/filing/0001628280-24-023064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/0001628280-24-023064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/ovid-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:53:20.532887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0165d5b4c45ae7541bc548dc6096870cc205315","claim":"Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"Ovid Therapeutics Inc. (the \"Company\") issued a press release announcing Business Update, First Quarter 2024 Financial Results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/0001628280-24-023064-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}